§

Ex Parte Wurtman et al

12162759 - (D) (P.T.A.B. Feb. 26, 2019)
Ex Parte Wurtman et al

15 Cited authorities

  1. KSR International Co. v. Teleflex Inc.

    550 U.S. 398 (2007)   Cited 1,547 times   185 Legal Analyses
    Holding that, in an obviousness analysis, "[r]igid preventative rules that deny factfinders recourse to common sense, however, are neither necessary under our case law nor consistent with it"

  2. In re Kubin

    561 F.3d 1351 (Fed. Cir. 2009)   Cited 134 times   10 Legal Analyses
    Finding patent invalid where an inherent benefit "is not an additional requirement imposed by the claims . . . but rather a property necessarily present" when the other limitations are satisfied

  3. In re Am. Academy of Science Tech Ctr.

    367 F.3d 1359 (Fed. Cir. 2004)   Cited 88 times   1 Legal Analyses
    Holding that descriptions of deficiencies of using mainframe computers set out in the "Background of the Invention" portion of the specification did not exclude mainframes from the definition of "'user computer'" where the "specification as a whole" did not express a clear disavowal of that subject matter

  4. In re Gurley

    27 F.3d 551 (Fed. Cir. 1994)   Cited 102 times   3 Legal Analyses
    Upholding obviousness finding where patent was directed to one of two alternative resins disclosed in prior art reference, even though reference described claimed resin as "inferior."

  5. Jansen v. Rexall Sundown, Inc.

    342 F.3d 1329 (Fed. Cir. 2003)   Cited 52 times   2 Legal Analyses
    Holding that a method of treating ... a male human in need of such treatment means a method practiced for the stated purpose

  6. Rapoport v. Dement

    254 F.3d 1053 (Fed. Cir. 2001)   Cited 55 times   3 Legal Analyses
    Finding no inherent anticipation where intent for administering buspirone as part of asserted claims - to treat sleep apnea - resulted in manipulative difference from method disclosed in prior art - which was to treat anxiety; dosing regime for anxiety was three times daily while regime for sleep apnea was larger dose once a day at time of sleep

  7. In re Merck Co., Inc.

    800 F.2d 1091 (Fed. Cir. 1986)   Cited 70 times   2 Legal Analyses
    Holding that a person of skill in the art would have expected amitriptyline to resemble imipramine in the alleviation of depression in humans because of the drugs’ close structural similarity and similar use

  8. Eli Lilly & Co. v. Teva Pharmaceuticals USA, Inc.

    619 F.3d 1329 (Fed. Cir. 2010)   Cited 21 times
    Rejecting an enablement challenge to patents that were filed while clinical trial results were pending

  9. Meitzner v. Mindick

    549 F.2d 775 (C.C.P.A. 1977)   Cited 10 times   1 Legal Analyses

    Patent Appeal No. 76-577. February 24, 1977. Rehearing Denied April 28, 1977. Eugene Sabol, Fisher, Christen Sabol, Washington, D.C., attys. of record, for appellants; George W.F. Simmons, Robert A. Doherty, Rohm Haas Co., Philadelphia, Pa., of counsel. Herbert B. Keil, Michael P. Bucklo, Johnston, Keil, Thompson Shurtleff, Chicago, Ill., David B. Kellom, Bernd W. Sandt, Midland, Mich., attys. of record, for appellees. Appeal from the Board of Patent Interferences. Before MARKEY, Chief Judge, and

  10. Section 112 - Specification

    35 U.S.C. § 112   Cited 7,363 times   1046 Legal Analyses
    Requiring patent applications to include a "specification" that provides, among other information, a written description of the invention and of the manner and process of making and using it

  11. Section 103 - Conditions for patentability; non-obvious subject matter

    35 U.S.C. § 103   Cited 6,130 times   479 Legal Analyses
    Holding the party seeking invalidity must prove "the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains."

  12. Section 6 - Patent Trial and Appeal Board

    35 U.S.C. § 6   Cited 186 times   63 Legal Analyses
    Giving the Director authority to designate "at least 3 members of the Patent Trial and Appeal Board" to review "[e]ach appeal, derivation proceeding, post-grant review, and inter partes review"

  13. Section 371 - National stage: Commencement

    35 U.S.C. § 371   Cited 52 times   81 Legal Analyses
    Referring to the "requirements" in specific "subsection"

  14. Section 1.136 - Extensions of time

    37 C.F.R. § 1.136   Cited 17 times   30 Legal Analyses

    (a) (1) If an applicant is required to reply within a nonstatutory or shortened statutory time period, applicant may extend the time period for reply up to the earlier of the expiration of any maximum period set by statute or five months after the time period set for reply, if a petition for an extension of time and the fee set in § 1.17(a) are filed, unless: (i) Applicant is notified otherwise in an Office action; (ii) The reply is a reply brief submitted pursuant to § 41.41 of this title; (iii)

  15. Section 1.68 - Declaration in lieu of oath

    37 C.F.R. § 1.68   Cited 6 times

    Any document to be filed in the Patent and Trademark Office and which is required by any law, rule, or other regulation to be under oath may be subscribed to by a written declaration. Such declaration may be used in lieu of the oath otherwise required, if, and only if, the declarant is on the same document, warned that willful false statements and the like are punishable by fine or imprisonment, or both (18 U.S.C. 1001 ) and may jeopardize the validity of the application or any patent issuing thereon